{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T21:40:33Z","timestamp":1788817233616,"version":"build-2803163510"},"reference-count":113,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T00:00:00Z","timestamp":1688428800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T00:00:00Z","timestamp":1688428800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"the academic promotion program of Shandong First Medical University","award":["2019LJ003"],"award-info":[{"award-number":["2019LJ003"]}]},{"name":"the academic promotion program of Shandong First Medical University","award":["2019QL011"],"award-info":[{"award-number":["2019QL011"]}]},{"name":"Shandong Province post-doctoral innovation projects","award":["202003084"],"award-info":[{"award-number":["202003084"]}]},{"name":"Projects of medical and health technology development program in Shandong province","award":["202213020257"],"award-info":[{"award-number":["202213020257"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>In recent years, cancer immunotherapy has emerged as an exciting cancer treatment. Immune checkpoint blockade brings new opportunities for more researchers and clinicians. Programmed cell death receptor-1 (PD-1) is a widely studied immune checkpoint, and PD-1 blockade therapy has shown promising results in a variety of tumors, including melanoma, non-small cell lung cancer and renal cell carcinoma, which greatly improves patient overall survival and becomes a promising tool for the eradication of metastatic or inoperable tumors. However, low responsiveness and immune-related adverse effects currently limit its clinical application. Overcoming these difficulties is a major challenge to improve PD-1 blockade therapies. Nanomaterials have unique properties that enable targeted drug delivery, combination therapy through multidrug co-delivery strategies, and controlled drug release through sensitive bonds construction. In recent years, combining nanomaterials with PD-1 blockade therapy to construct novel single-drug-based or combination therapy-based nano-delivery systems has become an effective mean to address the limitations of PD-1 blockade therapy. In this study, the application of nanomaterial carriers in individual delivery of PD-1 inhibitors, combined delivery of PD-1 inhibitors and other immunomodulators, chemotherapeutic drugs, photothermal reagents were reviewed, which provides effective references for designing new PD-1 blockade therapeutic strategies.<\/jats:p>\n                  <jats:p>\n                    <jats:bold>Graphical Abstract<\/jats:bold>\n                  <\/jats:p>","DOI":"10.1186\/s12951-023-01966-4","type":"journal-article","created":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T17:01:42Z","timestamp":1688490102000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":37,"title":["Advances in PD-1 signaling inhibition-based nano-delivery systems for tumor therapy"],"prefix":"10.1186","volume":"21","author":[{"given":"Songlin","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiyang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinzhe","family":"Shao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haonan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shushu","family":"Chao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoju","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingqiang","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pingping","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,4]]},"reference":[{"key":"1966_CR1","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.3389\/fphar.2018.01253","volume":"9","author":"QY Zhang","year":"2018","unstructured":"Zhang QY, Wang FX, Jia KK, Kong LD. Natural product interventions for chemotherapy and radiotherapy-induced side effects. Front Pharmacol. 2018;9:1253.","journal-title":"Front Pharmacol"},{"key":"1966_CR2","first-page":"141","volume":"2","author":"X Wang","year":"2019","unstructured":"Wang X, Zhang H, Chen X. Drug resistance and combating drug resistance in cancer. Cancer Drug Resistance. 2019;2:141\u201360.","journal-title":"Cancer Drug Resistance"},{"key":"1966_CR3","first-page":"8","volume":"30","author":"XD Zhang","year":"2018","unstructured":"Zhang XD, Wang C, Wang JQ, Hu QY, Langworthy B, Ye YQ, Sun WJ, Lin J, Wang TF, Fine J, Cheng H, Dotti G, Huang P, Gu Z. PD-1 blockade cellular vesicles for cancer immunotherapy. Adv Mater. 2018;30:8.","journal-title":"Adv Mater"},{"key":"1966_CR4","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1186\/s12916-016-0623-5","volume":"14","author":"S Farkona","year":"2016","unstructured":"Farkona S, Diamandis EP, Blasutig IM. Cancer immunotherapy: the beginning of the end of cancer? BMC Med. 2016;14:73.","journal-title":"BMC Med"},{"key":"1966_CR5","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1038\/nature10673","volume":"480","author":"I Mellman","year":"2011","unstructured":"Mellman I, Coukos G, Dranoff G. Cancer immunotherapy comes of age. Nature. 2011;480:480\u20139.","journal-title":"Nature"},{"key":"1966_CR6","doi-asserted-by":"publisher","first-page":"3887","DOI":"10.1002\/j.1460-2075.1992.tb05481.x","volume":"11","author":"Y Ishida","year":"1992","unstructured":"Ishida Y, Agata Y, Shibahara K, Honjo T. Induced expression of PD-1, a novel member of the immunoglobulin gene superfamily, upon programmed cell death. EMBO J. 1992;11:3887\u201395.","journal-title":"EMBO J"},{"key":"1966_CR7","doi-asserted-by":"publisher","first-page":"eabd2712","DOI":"10.1126\/sciadv.abd2712","volume":"6","author":"N Patsoukis","year":"2020","unstructured":"Patsoukis N, Wang Q, Strauss L, Boussiotis VA. Revisiting the PD-1 pathway. Sci Adv. 2020;6:eabd2712.","journal-title":"Sci Adv"},{"key":"1966_CR8","doi-asserted-by":"publisher","first-page":"945","DOI":"10.4049\/jimmunol.173.2.945","volume":"173","author":"JM Chemnitz","year":"2004","unstructured":"Chemnitz JM, Parry RV, Nichols KE, June CH, Riley JL. SHP-1 and SHP-2 associate with immunoreceptor tyrosine-based switch motif of programmed death 1 upon primary human Tcell stimulation, but only receptor ligation prevents T cell activation. J Immunol. 2004;173:945.","journal-title":"J Immunol"},{"key":"1966_CR9","doi-asserted-by":"publisher","first-page":"195","DOI":"10.1016\/j.it.2006.02.001","volume":"27","author":"T Okazaki","year":"2006","unstructured":"Okazaki T, Honjo T. The PD-1\u2013PD-L pathway in immunological tolerance. Trends Immunol. 2006;27:195\u2013201.","journal-title":"Trends Immunol"},{"key":"1966_CR10","doi-asserted-by":"publisher","first-page":"eaay4458","DOI":"10.1126\/sciadv.aay4458","volume":"6","author":"M Marasco","year":"2020","unstructured":"Marasco M, Berteotti A, Weyershaeuser J, Thorausch N, Sikorska J, Krausze J, Brandt HJ, Kirkpatrick J, Rios P, Schamel WW, K\u00f6hn M, Carlomagno T. Molecular mechanism of SHP2 activation by PD-1 stimulation. Sci Adv. 2020;6:eaay4458.","journal-title":"Sci Adv"},{"key":"1966_CR11","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3389\/fonc.2018.00086","volume":"8","author":"JA Seidel","year":"2018","unstructured":"Seidel JA, Otsuka A, Kabashima K. Anti-PD-1 and Anti-CTLA-4 therapies in cancer: mechanisms of action, efficacy, and limitations. Front Oncol. 2018;8:86.","journal-title":"Front Oncol"},{"key":"1966_CR12","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nature22396","volume":"545","author":"SR Gordon","year":"2017","unstructured":"Gordon SR, Maute RL, Dulken BW, Hutter G, George BM, Mccracken MN, Gupta R, Tsai JM, Sinha R, Corey D, Ring AM, Connolly AJ, Weissman IL. PD-1 expression by tumour-associated macrophages inhibits phagocytosis and tumour immunity. Nature. 2017;545:495\u20139.","journal-title":"Nature"},{"key":"1966_CR13","doi-asserted-by":"publisher","first-page":"1134","DOI":"10.1007\/s12094-020-02499-0","volume":"23","author":"J Ruan","year":"2021","unstructured":"Ruan J, Ouyang M, Zhang W, Luo Y, Zhou D. The effect of PD-1 expression on tumor-associated macrophage in T cell lymphoma. Clin Transl Oncol. 2021;23:1134\u201341.","journal-title":"Clin Transl Oncol"},{"key":"1966_CR14","doi-asserted-by":"publisher","first-page":"4545","DOI":"10.4049\/jimmunol.1402550","volume":"194","author":"APR Bally","year":"2015","unstructured":"Bally APR, Lu P, Tang Y, Austin JW, Scharer CD, Ahmed R, Boss JM. NF-\u03baB regulates PD-1 expression in macrophages. J Immunol. 2015;194:4545.","journal-title":"J Immunol"},{"key":"1966_CR15","doi-asserted-by":"publisher","first-page":"6143","DOI":"10.1038\/onc.2017.209","volume":"36","author":"Y Liu","year":"2017","unstructured":"Liu Y, Cheng Y, Xu Y, Wang Z, Du X, Li C, Peng J, Gao L, Liang X, Ma C. Increased expression of programmed cell death protein 1 on NK cells inhibits NK-cell-mediated anti-tumor function and indicates poor prognosis in digestive cancers. Oncogene. 2017;36:6143\u201353.","journal-title":"Oncogene"},{"key":"1966_CR16","doi-asserted-by":"publisher","first-page":"1809","DOI":"10.1182\/blood-2017-07-796342","volume":"131","author":"F Vari","year":"2018","unstructured":"Vari F, Arpon D, Keane C, Hertzberg MS, Talaulikar D, Jain S, Cui Q, Han E, Tobin J, Bird R, Cross D, Hernandez A, Gould C, Birch S, Gandhi MK. Immune evasion via PD-1\/PD-L1 on NK cells and monocyte\/macrophages is more prominent in Hodgkin lymphoma than DLBCL. Blood. 2018;131:1809\u201319.","journal-title":"Blood"},{"key":"1966_CR17","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2015.1085146","volume":"5","author":"TS Lim","year":"2016","unstructured":"Lim TS, Chew V, Sieow JL, Goh S, Yeong JPS, Soon AL, Ricciardi-Castagnoli P. PD-1 expression on dendritic cells suppresses CD8+ T cell function and antitumor immunity. OncoImmunology. 2016;5:e1085146.","journal-title":"OncoImmunology"},{"key":"1966_CR18","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1038\/s41590-020-0801-7","volume":"21","author":"HI Aksoylar","year":"2020","unstructured":"Aksoylar HI, Boussiotis VA. PD-1(+) T(reg) cells: a foe in cancer immunotherapy? Nat Immunol. 2020;21:1311\u20132.","journal-title":"Nat Immunol"},{"key":"1966_CR19","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2019.105999","volume":"77","author":"M Xie","year":"2019","unstructured":"Xie M, Huang X, Ye X, Qian W. Prognostic and clinicopathological significance of PD-1\/PD-L1 expression in the tumor microenvironment and neoplastic cells for lymphoma. Int Immunopharmacol. 2019;77:105999.","journal-title":"Int Immunopharmacol"},{"key":"1966_CR20","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.1016\/j.cell.2015.08.052","volume":"162","author":"S Kleffel","year":"2015","unstructured":"Kleffel S, Posch C, Barthel SR, Mueller H, Schlapbach C, Guenova E, Elco CP, Lee N, Juneja VR, Zhan Q, Lian CG, Thomi R, Hoetzenecker W, Cozzio A, Dummer R, Mihm MC, Flaherty KT, Frank MH, Murphy GF, Sharpe AH, Kupper TS, Schatton T. Melanoma Cell-intrinsic PD-1 receptor functions promote tumor growth. Cell. 2015;162:1242\u201356.","journal-title":"Cell"},{"key":"1966_CR21","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1016\/j.celrep.2018.06.054","volume":"24","author":"Y Zhao","year":"2018","unstructured":"Zhao Y, Harrison DL, Song Y, Ji J, Huang J, Hui E. Antigen-presenting cell-intrinsic PD-1 neutralizes PD-L1 in cis to attenuate PD-1 signaling in T cells. Cell Rep. 2018;24:379-390.e6.","journal-title":"Cell Rep"},{"key":"1966_CR22","doi-asserted-by":"publisher","first-page":"635","DOI":"10.3389\/fimmu.2018.00635","volume":"9","author":"C Mehrfeld","year":"2018","unstructured":"Mehrfeld C, Zenner S, Kornek M, Lukacs-Kornek V. The contribution of non-professional antigen-presenting cells to immunity and tolerance in the liver. Front Immunol. 2018;9:635.","journal-title":"Front Immunol"},{"key":"1966_CR23","doi-asserted-by":"publisher","first-page":"1632","DOI":"10.3390\/cells10071632","volume":"10","author":"A Rugamba","year":"2021","unstructured":"Rugamba A, Kang DY, Sp N, Jo ES, Lee J-M, Bae SW, Jang K-J. Silibinin regulates tumor progression and tumorsphere formation by suppressing PD-L1 expression in non-small cell lung cancer (NSCLC) cells. Cells. 2021;10:1632.","journal-title":"Cells"},{"key":"1966_CR24","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s12967-017-1150-7","volume":"15","author":"G Botti","year":"2017","unstructured":"Botti G, Fratangelo F, Cerrone M, Liguori G, Cantile M, Anniciello AM, Scala S, D\u2019alterio C, Trimarco C, Ianaro A, Cirino G, Carac\u00f2 C, Colombino M, Palmieri G, Pepe S, Ascierto PA, Sabbatino F, Scognamiglio G. COX-2 expression positively correlates with PD-L1 expression in human melanoma cells. J Transl Med. 2017;15:46.","journal-title":"J Transl Med"},{"key":"1966_CR25","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1097\/PAI.0000000000000766","volume":"28","author":"J Carlsson","year":"2020","unstructured":"Carlsson J, Sundqvist P, Kosuta V, F\u00e4lt A, Giunchi F, Fiorentino M, Davidsson SJ. PD-L1 expression is associated with poor prognosis in renal cell carcinoma. Appl Immunohistochem Mol Morphol. 2020;28:213\u201320.","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"1966_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2021.120988","volume":"275","author":"C Chen","year":"2021","unstructured":"Chen C, Guo Q, Fu H, Yu J, Wang L, Sun Y, Zhang J, Duan Y. Asynchronous blockade of PD-L1 and CD155 by polymeric nanoparticles inhibits triple-negative breast cancer progression and metastasis. Biomaterials. 2021;275:120988.","journal-title":"Biomaterials"},{"key":"1966_CR27","doi-asserted-by":"publisher","first-page":"8318","DOI":"10.1021\/acs.nanolett.9b03968","volume":"19","author":"S Ruan","year":"2019","unstructured":"Ruan S, Xie R, Qin L, Yu M, Xiao W, Hu C, Yu W, Qian Z, Ouyang L, He Q, Gao H. Aggregable nanoparticles-enabled chemotherapy and autophagy inhibition combined with anti-PD-L1 antibody for improved glioma treatment. Nano Lett. 2019;19:8318\u201332.","journal-title":"Nano Lett"},{"key":"1966_CR28","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.semcancer.2022.03.016","volume":"86","author":"Q Ye","year":"2022","unstructured":"Ye Q, Lin Y, Li R, Wang H, Dong C. Recent advances of nanodrug delivery system in the treatment of hematologic malignancies. Semin Cancer Biol. 2022;86:607\u201323.","journal-title":"Semin Cancer Biol"},{"key":"1966_CR29","doi-asserted-by":"publisher","first-page":"4263","DOI":"10.1021\/acsnano.1c10283","volume":"16","author":"L Guan","year":"2022","unstructured":"Guan L, Zhang Z, Gao T, Fu S, Mu W, Liang S, Liu Y, Chu Q, Fang Y, Liu Y. Depleting tumor infiltrating B cells to boost antitumor immunity with tumor immune-microenvironment reshaped hybrid nanocage. ACS Nano. 2022;16:4263\u201377.","journal-title":"ACS Nano"},{"key":"1966_CR30","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.jconrel.2022.01.034","volume":"344","author":"Y Wang","year":"2022","unstructured":"Wang Y, Sun T, Jiang C. Nanodrug delivery systems for ferroptosis-based cancer therapy. J Control Release. 2022;344:289\u2013301.","journal-title":"J Control Release"},{"key":"1966_CR31","doi-asserted-by":"publisher","first-page":"933","DOI":"10.1158\/2159-8290.CD-20-1808","volume":"11","author":"L Bejarano","year":"2021","unstructured":"Bejarano L, Jord\u0101o MJC, Joyce JA. Therapeutic targeting of the tumor microenvironment. Cancer Discov. 2021;11:933\u201359.","journal-title":"Cancer Discov"},{"key":"1966_CR32","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3390\/medicina56010015","volume":"56","author":"B Arneth","year":"2020","unstructured":"Arneth B. Tumor microenvironment. Medicina. 2020;56:15.","journal-title":"Medicina"},{"key":"1966_CR33","doi-asserted-by":"publisher","first-page":"747","DOI":"10.3390\/cells8070747","volume":"8","author":"V Quaranta","year":"2019","unstructured":"Quaranta V, Schmid MC. Macrophage-mediated subversion of anti-Tumour immunity. Cells. 2019;8:747.","journal-title":"Cells"},{"key":"1966_CR34","doi-asserted-by":"publisher","DOI":"10.1038\/cddis.2016.33","volume":"7","author":"W Chen","year":"2016","unstructured":"Chen W, Wang J, Jia L, Liu J, Tian Y. Attenuation of the programmed cell death-1 pathway increases the M1 polarization of macrophages induced by zymosan. Cell Death Dis. 2016;7:e2115.","journal-title":"Cell Death Dis"},{"key":"1966_CR35","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1208\/s12249-021-01933-y","volume":"22","author":"MS Hanafy","year":"2021","unstructured":"Hanafy MS, Hufnagel S, Trementozzi AN, Sakran W, Stachowiak JC, Koleng JJ, Cui Z. PD-1 siRNA-encapsulated solid lipid nanoparticles downregulate PD-1 expression by macrophages and inhibit tumor growth. AAPS PharmSciTech. 2021;22:60.","journal-title":"AAPS PharmSciTech"},{"key":"1966_CR36","doi-asserted-by":"publisher","first-page":"1548","DOI":"10.1158\/2326-6066.CIR-18-0062","volume":"6","author":"F Concha-Benavente","year":"2018","unstructured":"Concha-Benavente F, Kansy B, Moskovitz J, Moy J, Chandran U, Ferris RL. PD-L1 mediates dysfunction in activated PD-1+ NK cells in head and neck cancer patients. Cancer Immunol Res. 2018;6:1548.","journal-title":"Cancer Immunol Res"},{"key":"1966_CR37","doi-asserted-by":"publisher","first-page":"1242","DOI":"10.3389\/fimmu.2019.01242","volume":"10","author":"S Pesce","year":"2019","unstructured":"Pesce S, Greppi M, Grossi F, Del Zotto G, Moretta L, Sivori S, Genova C, Marcenaro E. PD\/1-PD-Ls checkpoint: insight on the potential role of NK cells. Front Immunol. 2019;10:1242.","journal-title":"Front Immunol"},{"key":"1966_CR38","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1007\/s00262-020-02681-x","volume":"70","author":"A Makowska","year":"2021","unstructured":"Makowska A, Meier S, Shen L, Busson P, Baloche V, Kontny U. Anti-PD-1 antibody increases NK cell cytotoxicity towards nasopharyngeal carcinoma cells in the context of chemotherapy-induced upregulation of PD-1 and PD-L1. Cancer Immunol Immunother. 2021;70:323\u201336.","journal-title":"Cancer Immunol Immunother"},{"key":"1966_CR39","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003031","volume":"9","author":"YF Zhou","year":"2021","unstructured":"Zhou YF, Song SS, Tian MX, Tang Z, Wang H, Fang Y, Qu WF, Jiang XF, Tao CY, Huang R, Zhou PY, Zhu SG, Zhou J, Fan J, Liu WR, Shi YH. Cystathionine \u03b2-synthase mediated PRRX2\/IL-6\/STAT3 inactivation suppresses Tregs infiltration and induces apoptosis to inhibit HCC carcinogenesis. J Immunother Cancer. 2021;9:e003031.","journal-title":"J Immunother Cancer"},{"key":"1966_CR40","doi-asserted-by":"publisher","first-page":"9999","DOI":"10.1073\/pnas.1822001116","volume":"116","author":"T Kamada","year":"2019","unstructured":"Kamada T, Togashi Y, Tay C, Ha D, Sasaki A, Nakamura Y, Sato E, Fukuoka S, Tada Y, Tanaka A, Morikawa H, Kawazoe A, Kinoshita T, Shitara K, Sakaguchi S, Nishikawa H. PD-1+ regulatory T cells amplified by PD-1 blockade promote hyperprogression of cancer. Proc Natl Acad Sci. 2019;116:9999.","journal-title":"Proc Natl Acad Sci"},{"key":"1966_CR41","doi-asserted-by":"publisher","first-page":"1491","DOI":"10.1007\/s00262-016-1906-6","volume":"65","author":"L Dyck","year":"2016","unstructured":"Dyck L, Wilk MM, Raverdeau M, Misiak A, Boon L, Mills KHG. Anti-PD-1 inhibits Foxp3+ Treg cell conversion and unleashes intratumoural effector T cells thereby enhancing the efficacy of a cancer vaccine in a mouse model. Cancer Immunol Immunother. 2016;65:1491\u20138.","journal-title":"Cancer Immunol Immunother"},{"key":"1966_CR42","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1038\/s41590-020-0769-3","volume":"21","author":"S Kumagai","year":"2020","unstructured":"Kumagai S, Togashi Y, Kamada T, Sugiyama E, Nishinakamura H, Takeuchi Y, Vitaly K, Itahashi K, Maeda Y, Matsui S, Shibahara T, Yamashita Y, Irie T, Tsuge A, Fukuoka S, Kawazoe A, Udagawa H, Kirita K, Aokage K, Ishii G, Kuwata T, Nakama K, Kawazu M, Ueno T, Yamazaki N, Goto K, Tsuboi M, Mano H, Doi T, Shitara K, Nishikawa H. The PD-1 expression balance between effector and regulatory T cells predicts the clinical efficacy of PD-1 blockade therapies. Nat Immunol. 2020;21:1346\u201358.","journal-title":"Nat Immunol"},{"key":"1966_CR43","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1158\/0008-5472.CAN-15-0748","volume":"76","author":"L Karyampudi","year":"2016","unstructured":"Karyampudi L, Lamichhane P, Krempski J, Kalli KR, Behrens MD, Vargas DM, Hartmann LC, Janco JMT, Dong H, Hedin KE. PD-1 blunts the function of ovarian tumor\u2013infiltrating dendritic cells by inactivating NF-\u03baB. Cancer Res. 2016;76:239\u201350.","journal-title":"Cancer Res"},{"key":"1966_CR44","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3389\/fimmu.2018.00394","volume":"9","author":"M Versteven","year":"2018","unstructured":"Versteven M, Van Den Bergh JMJ, Marcq E, Smits ELJ, Van Tendeloo VFI, Hobo W, Lion E. Dendritic cells and programmed death-1 blockade: a joint venture to combat cancer. Front Immunol. 2018;9:394.","journal-title":"Front Immunol"},{"key":"1966_CR45","doi-asserted-by":"publisher","first-page":"953","DOI":"10.4049\/jimmunol.1502291","volume":"197","author":"XLR Iraolagoitia","year":"2016","unstructured":"Iraolagoitia XLR, Spallanzani RG, Torres NI, Araya RE, Ziblat A, Domaica CI, Sierra JM, Nu\u00f1ez SY, Secchiari F, Gajewski TF, Zwirner NW, Fuertes MB. NK Cells restrain spontaneous antitumor CD8+ T cell priming through PD-1\/PD-L1 interactions with dendritic cells. J Immunol. 2016;197:953.","journal-title":"J Immunol"},{"key":"1966_CR46","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1016\/j.actbio.2021.02.026","volume":"133","author":"D Stoycheva","year":"2021","unstructured":"Stoycheva D, Simsek H, Weber W, Hauser AE, Klotzsch E. External cues to drive B cell function towards immunotherapy. Acta Biomater. 2021;133:222\u201330.","journal-title":"Acta Biomater"},{"key":"1966_CR47","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1093\/qjmed\/hcz162","volume":"115","author":"X Sun","year":"2022","unstructured":"Sun X, Zhang T, Li M, Yin L, Xue J. Immunosuppressive B cells expressing PD-1\/PD-L1 in solid tumors: a mini review. QJM-Int J Med. 2022;115:507\u201312.","journal-title":"QJM-Int J Med"},{"key":"1966_CR48","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1016\/j.molimm.2019.02.009","volume":"109","author":"X Wang","year":"2019","unstructured":"Wang X, Wang G, Wang Z, Liu B, Han N, Li J, Lu C, Liu X, Zhang Q, Yang Q, Wang G. PD-1-expressing B cells suppress CD4+ and CD8+ T cells via PD-1\/PD-L1-dependent pathway. Mol Immunol. 2019;109:20\u20136.","journal-title":"Mol Immunol"},{"key":"1966_CR49","doi-asserted-by":"publisher","first-page":"661","DOI":"10.3390\/nano11030661","volume":"11","author":"C Cremolini","year":"2021","unstructured":"Cremolini C, Vitale E, Rastaldo R, Giachino C. Advanced nanotechnology for enhancing immune checkpoint blockade therapy. Nanomaterials. 2021;11:661.","journal-title":"Nanomaterials"},{"key":"1966_CR50","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.intimp.2018.06.001","volume":"62","author":"KM Hargadon","year":"2018","unstructured":"Hargadon KM, Johnson CE, Williams CJ. Immune checkpoint blockade therapy for cancer: an overview of FDA-approved immune checkpoint inhibitors. Int Immunopharmacol. 2018;62:29\u201339.","journal-title":"Int Immunopharmacol"},{"key":"1966_CR51","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/j.drudis.2019.11.003","volume":"25","author":"S Singh","year":"2020","unstructured":"Singh S, Hassan D, Aldawsari HM, Molugulu N, Shukla R, Kesharwani P. Immune checkpoint inhibitors: a promising anticancer therapy. Drug Discov Today. 2020;25:223\u20139.","journal-title":"Drug Discov Today"},{"key":"1966_CR52","doi-asserted-by":"publisher","first-page":"e1786","DOI":"10.1002\/onco.13887","volume":"26","author":"E Chang","year":"2021","unstructured":"Chang E, Pelosof L, Lemery S, Gong Y, Goldberg KB, Farrell AT, Keegan P, Veeraraghavan J, Wei G, Blumenthal GM, Amiri-Kordestani L, Singh H, Fashoyin-Aje L, Gormley N, Kluetz PG, Pazdur R, Beaver JA, Theoret MR. Systematic review of PD-1\/PD-L1 inhibitors in oncology: from personalized medicine to public health. Oncologist. 2021;26:e1786\u201399.","journal-title":"Oncologist"},{"key":"1966_CR53","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.canlet.2018.04.031","volume":"434","author":"RJ Boohaker","year":"2018","unstructured":"Boohaker RJ, Sambandam V, Segura I, Miller J, Suto M, Xu B. Rational design and development of a peptide inhibitor for the PD-1\/PD-L1 interaction. Cancer Lett. 2018;434:11\u201321.","journal-title":"Cancer Lett"},{"key":"1966_CR54","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmc.2021.116038","volume":"33","author":"X Wu","year":"2021","unstructured":"Wu X, Meng Y, Liu L, Gong G, Zhang H, Hou Y, Liu C, Wu D, Qin M. Insights into non-peptide small-molecule inhibitors of the PD-1\/PD-L1 interaction: development and perspective. Bioorg Med Chem. 2021;33:116038.","journal-title":"Bioorg Med Chem"},{"key":"1966_CR55","doi-asserted-by":"publisher","DOI":"10.15252\/emmm.201911571","volume":"12","author":"Z Fan","year":"2020","unstructured":"Fan Z, Tian Y, Chen Z, Liu L, Zhou Q, He J, Coleman J, Dong C, Li N, Huang J, Xu C, Zhang Z, Gao S, Zhou P, Ding K, Chen L. Blocking interaction between SHP2 and PD-1 denotes a novel opportunity for developing PD-1 inhibitors. EMBO Mol Med. 2020;12:e11571.","journal-title":"EMBO Mol Med"},{"key":"1966_CR56","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1038\/s41419-019-1418-3","volume":"10","author":"T Zhao","year":"2019","unstructured":"Zhao T, Wei T, Guo J, Wang Y, Shi X, Guo S, Jia X, Jia H, Feng Z. PD-1-siRNA delivered by attenuated Salmonella enhances the antimelanoma effect of pimozide. Cell Death Dis. 2019;10:164.","journal-title":"Cell Death Dis"},{"key":"1966_CR57","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1093\/annonc\/mdv383","volume":"26","author":"J Naidoo","year":"2015","unstructured":"Naidoo J, Page DB, Li BT, Connell LC, Schindler K, Lacouture ME, Postow MA, Wolchok JD. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol. 2015;26:2375\u201391.","journal-title":"Ann Oncol"},{"key":"1966_CR58","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s40425-018-0316-z","volume":"6","author":"J Gong","year":"2018","unstructured":"Gong J, Chehrazi-Raffle A, Reddi S, Salgia R. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. J Immunother Cancer. 2018;6:8.","journal-title":"J Immunother Cancer"},{"key":"1966_CR59","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1038\/s41467-020-14425-7","volume":"11","author":"Y Huang","year":"2020","unstructured":"Huang Y, Chen Y, Zhou S, Chen L, Wang J, Pei Y, Xu M, Feng J, Jiang T, Liang K, Liu S, Song Q, Jiang G, Gu X, Zhang Q, Gao X, Chen J. Dual-mechanism based CTLs infiltration enhancement initiated by nano-sapper potentiates immunotherapy against immune-excluded tumors. Nat Commun. 2020;11:622.","journal-title":"Nat Commun"},{"key":"1966_CR60","volume":"8","author":"AJ Oliver","year":"2019","unstructured":"Oliver AJ, Davey AS, Keam SP, Mardiana S, Chan JD, Von Scheidt B, Beavis PA, House IG, Van Audernaerde JRM, Darcy PK, Kershaw MH, Slaney CY. Tissue-specific tumor microenvironments influence responses to immunotherapies. Clinl Transl Immunol. 2019;8:e1094.","journal-title":"Clinl Transl Immunol"},{"key":"1966_CR61","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1007\/s00262-022-03154-z","volume":"71","author":"M Ito","year":"2022","unstructured":"Ito M, Mimura K, Nakajima S, Saito K, Min AKT, Okayama H, Saito M, Momma T, Saze Z, Ohtsuka M, Yamamoto T, Kono K. Immune escape mechanism behind resistance to anti-PD-1 therapy in gastrointestinal tract metastasis in malignant melanoma patients with multiple metastases. Cancer Immunol Immunother. 2022;71:2293\u2013300.","journal-title":"Cancer Immunol Immunother"},{"key":"1966_CR62","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1016\/j.cell.2016.02.065","volume":"165","author":"W Hugo","year":"2016","unstructured":"Hugo W, Zaretsky JM, Sun L, Song C, Moreno BH, Hu-Lieskovan S, Berent-Maoz B, Pang J, Chmielowski B, Cherry G, Seja E, Lomeli S, Kong X, Kelley MC, Sosman JA, Johnson DB, Ribas A, Lo RS. Genomic and transcriptomic features of response to anti-PD-1 therapy in metastatic melanoma. Cell. 2016;165:35\u201344.","journal-title":"Cell"},{"key":"1966_CR63","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1016\/j.ccell.2017.05.010","volume":"31","author":"G Abril-Rodriguez","year":"2017","unstructured":"Abril-Rodriguez G, Ribas A. SnapShot: immune checkpoint inhibitors. Cancer Cell. 2017;31:848-848.e1.","journal-title":"Cancer Cell"},{"key":"1966_CR64","doi-asserted-by":"publisher","first-page":"1703135","DOI":"10.1002\/adma.201703135","volume":"29","author":"X Liang","year":"2017","unstructured":"Liang X, Gao C, Cui L, Wang S, Wang J, Dai Z. Self-assembly of an amphiphilic janus camptothecin\u2013floxuridine conjugate into liposome-like nanocapsules for more efficacious combination chemotherapy in cancer. Adv Mater. 2017;29:1703135.","journal-title":"Adv Mater"},{"key":"1966_CR65","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1021\/acsnano.8b06164","volume":"13","author":"X Liu","year":"2018","unstructured":"Liu X, Jiang J, Chan R, Ji Y, Lu J, Liao YP, Okene M, Lin J, Lin P, Chang CH. Improved efficacy and reduced toxicity using a custom-designed irinotecan-delivering silicasome for orthotopic colon cancer. ACS Nano. 2018;13:38\u201353.","journal-title":"ACS Nano"},{"key":"1966_CR66","doi-asserted-by":"publisher","first-page":"2100833","DOI":"10.1002\/adhm.202100833","volume":"10","author":"Y Gao","year":"2021","unstructured":"Gao Y, Ouyang Z, Yang C, Song C, Jiang C, Song S, Shen M, Shi X. Overcoming T cell exhaustion via immune checkpoint modulation with a dendrimer-based hybrid nanocomplex. Adv Healthc Mater. 2021;10:2100833.","journal-title":"Adv Healthc Mater"},{"key":"1966_CR67","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/B978-0-12-814527-2.00006-8","volume-title":"Pharmaceutical applications of dendrimers","author":"PK Tripathi","year":"2020","unstructured":"Tripathi PK, Tripathi S. Dendrimers for anticancer drug delivery. In: Chauhan AS, Kulhari H, editors. Pharmaceutical applications of dendrimers. Amsterdam: Elsevier; 2020. p. 131\u201350."},{"key":"1966_CR68","doi-asserted-by":"publisher","first-page":"eaaw8922","DOI":"10.1126\/sciadv.aaw8922","volume":"5","author":"C Liu","year":"2019","unstructured":"Liu C, Wan T, Wang H, Zhang S, Ping Y, Cheng YJ. A boronic acid\u2013rich dendrimer with robust and unprecedented efficiency for cytosolic protein delivery and CRISPR-Cas9 gene editing. Sci Adv. 2019;5:eaaw8922.","journal-title":"Sci Adv"},{"key":"1966_CR69","doi-asserted-by":"publisher","first-page":"1902634","DOI":"10.1002\/adfm.201902634","volume":"30","author":"M Manzano","year":"2020","unstructured":"Manzano M, Vallet-Reg\u00ed MJ. Mesoporous silica nanoparticles for drug delivery. Adv Funct Mater. 2020;30:1902634.","journal-title":"Adv Funct Mater"},{"key":"1966_CR70","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1021\/acs.molpharmaceut.8b00810","volume":"16","author":"K Sztandera","year":"2018","unstructured":"Sztandera K, Gorzkiewicz M, Klajnert-Maculewicz BJMP. Gold nanoparticles in cancer treatment. Mol Pharm. 2018;16:1\u201323.","journal-title":"Mol Pharm"},{"key":"1966_CR71","doi-asserted-by":"publisher","first-page":"15587","DOI":"10.1002\/ange.202102631","volume":"133","author":"Z Geng","year":"2021","unstructured":"Geng Z, Wang L, Liu K, Liu J, Tan WJ. Enhancing anti-PD-1 immunotherapy by nanomicelles self-assembled from multivalent aptamer drug conjugates. Angew Chem Int. 2021;133:15587\u201393.","journal-title":"Angew Chem Int"},{"key":"1966_CR72","doi-asserted-by":"publisher","first-page":"21033","DOI":"10.1002\/anie.202108658","volume":"60","author":"Z Zhou","year":"2021","unstructured":"Zhou Z, Du C, Zhang Q, Yu G, Zhang F, Chen X. Exquisite vesicular nanomedicine by paclitaxel mediated co-assembly with camptothecin prodrug. Angew Chem Int Ed. 2021;60:21033\u20139.","journal-title":"Angew Chem Int Ed"},{"key":"1966_CR73","doi-asserted-by":"publisher","first-page":"17332","DOI":"10.1002\/anie.202002780","volume":"59","author":"S Yan","year":"2020","unstructured":"Yan S, Luo Z, Li Z, Wang Y, Tao J, Gong C, Liu X. Improving cancer immunotherapy outcomes using biomaterials. Angew Chem Int Ed. 2020;59:17332\u201343.","journal-title":"Angew Chem Int Ed"},{"key":"1966_CR74","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1515\/ntrev-2013-0013","volume":"3","author":"WH Gmeiner","year":"2014","unstructured":"Gmeiner WH, Ghosh S. Nanotechnology for cancer treatment. Nanotechnol Rev. 2014;3:111\u201322.","journal-title":"Nanotechnol Rev"},{"key":"1966_CR75","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1080\/1061186X.2017.1324860","volume":"25","author":"G Li","year":"2017","unstructured":"Li G, Song YZ, Huang ZJ, Chen K, Chen DW, Deng YQ. Novel, nano-sized, liposome-encapsulated polyamidoamine dendrimer derivatives facilitate tumour targeting by overcoming the polyethylene glycol dilemma and integrin saturation obstacle. J Drug Target. 2017;25:734\u201346.","journal-title":"J Drug Target"},{"key":"1966_CR76","doi-asserted-by":"publisher","first-page":"3199","DOI":"10.1038\/s41467-019-11157-1","volume":"10","author":"WL Liu","year":"2019","unstructured":"Liu WL, Zou MZ, Liu T, Zeng JY, Li X, Yu WY, Li CX, Ye JJ, Song W, Feng J, Zhang XZ. Cytomembrane nanovaccines show therapeutic effects by mimicking tumor cells and antigen presenting cells. Nat Commun. 2019;10:3199.","journal-title":"Nat Commun"},{"key":"1966_CR77","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2021.120795","volume":"605","author":"PV Nguyen","year":"2021","unstructured":"Nguyen PV, Allard-Vannier E, Chourpa I, Herv\u00e9-Aubert K. Nanomedicines functionalized with anti-EGFR ligands for active targeting in cancer therapy: biological strategy, design and quality control. Int J Pharm. 2021;605:120795.","journal-title":"Int J Pharm"},{"key":"1966_CR78","doi-asserted-by":"publisher","first-page":"9610","DOI":"10.1021\/acsami.6b00853","volume":"8","author":"M Xuan","year":"2016","unstructured":"Xuan M, Shao J, Dai L, Li J, He Q. Macrophage cell membrane camouflaged Au nanoshells for in vivo prolonged circulation life and enhanced cancer photothermal therapy. ACS Appl Mater Interfaces. 2016;8:9610\u20138.","journal-title":"ACS Appl Mater Interfaces"},{"key":"1966_CR79","doi-asserted-by":"publisher","first-page":"1906832","DOI":"10.1002\/smll.201906832","volume":"16","author":"Z Su","year":"2020","unstructured":"Su Z, Xiao Z, Wang Y, Huang J, An Y, Wang X, Shuai X. Codelivery of anti-PD-1 antibody and paclitaxel with matrix metalloproteinase and pH dual-sensitive micelles for enhanced tumor chemoimmunotherapy. Small. 2020;16:1906832.","journal-title":"Small"},{"key":"1966_CR80","doi-asserted-by":"publisher","first-page":"4879","DOI":"10.1021\/acs.nanolett.9b00584","volume":"19","author":"Q Chen","year":"2019","unstructured":"Chen Q, Chen G, Chen J, Shen J, Zhang X, Wang J, Chan A, Gu Z. Bioresponsive protein complex of aPD1 and aCD47 antibodies for enhanced immunotherapy. Nano Lett. 2019;19:4879\u201389.","journal-title":"Nano Lett"},{"key":"1966_CR81","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2020.103160","volume":"157","author":"M-J Sanaei","year":"2021","unstructured":"Sanaei M-J, Pourbagheri-Sigaroodi A, Kaveh V, Sheikholeslami SA, Salari S, Bashash D. The application of nano-medicine to overcome the challenges related to immune checkpoint blockades in cancer immunotherapy: recent advances and opportunities. Crit Rev Oncol Hemat. 2021;157:103160.","journal-title":"Crit Rev Oncol Hemat"},{"key":"1966_CR82","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.intimp.2018.12.034","volume":"68","author":"B Zhang","year":"2019","unstructured":"Zhang B, Zhou YL, Chen X, Wang Z, Wang Q, Ju F, Ren S, Xu R, Xue Q, Wu Q. Efficacy and safety of CTLA-4 inhibitors combined with PD-1 inhibitors or chemotherapy in patients with advanced melanoma. Int Immunopharmacol. 2019;68:131\u20136.","journal-title":"Int Immunopharmacol"},{"key":"1966_CR83","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.689727","volume":"9","author":"Y Fu","year":"2021","unstructured":"Fu Y, Peng Y, Zhao S, Mou J, Zeng L, Jiang X, Yang C, Huang C, Li Y, Lu Y, Wu M, Yang Y, Kong T, Lai Q, Wu Y, Yao Y, Wang Y, Gou L, Yang J. Combination foretinib and anti-PD-1 antibody immunotherapy for colorectal carcinoma. Front Cell Dev Biol. 2021;9:689727.","journal-title":"Front Cell Dev Biol"},{"key":"1966_CR84","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2021.121334","volume":"281","author":"R Maharjan","year":"2022","unstructured":"Maharjan R, Choi JU, Kweon S, Pangeni R, Lee NK, Park SJ, Chang KY, Park JW, Byun Y. A novel oral metronomic chemotherapy provokes tumor specific immunity resulting in colon cancer eradication in combination with anti-PD-1 therapy. Biomaterials. 2022;281:121334.","journal-title":"Biomaterials"},{"key":"1966_CR85","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1002\/advs.202003041","volume":"8","author":"XY Fang","year":"2021","unstructured":"Fang XY, Wu XL, Li ZD, Jiang LJ, Lo WS, Chen GM, Gu YJ, Wong WT. Biomimetic anti-PD-1 peptide-loaded 2D FePSe3 nanosheets for efficient photothermal and enhanced immune therapy with multimodal MR\/PA\/thermal imaging. Adv Sci. 2021;8:15.","journal-title":"Adv Sci"},{"key":"1966_CR86","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1089\/thy.2021.0371","volume":"32","author":"BC Bertol","year":"2021","unstructured":"Bertol BC, Bales ES, Calhoun JD, Mayberry A, Ledezma ML, Sams SB, Orlicky DJ, Donadi EA, Haugen BR, French JD. Lenvatinib plus anti-PD-1 combination therapy for advanced cancers: defining mechanisms of resistance in an inducible transgenic model of thyroid cancer. Thyroid. 2021;32:153\u201363.","journal-title":"Thyroid"},{"key":"1966_CR87","doi-asserted-by":"publisher","first-page":"1942","DOI":"10.1080\/21655979.2021.2023997","volume":"13","author":"L Wu","year":"2022","unstructured":"Wu L, Wang W, Tian J, Qi C, Cai Z, Yan W, Xuan S, Shang AJB. Combination therapy with Nab-paclitaxel and the interleukin-15 fused with anti-human serum albumin nanobody as a synergistic treatment for colorectal cancer. Bioengineered. 2022;13:1942\u201351.","journal-title":"Bioengineered"},{"key":"1966_CR88","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1172\/jci.insight.122700","volume":"3","author":"F Ordikhani","year":"2018","unstructured":"Ordikhani F, Uehara M, Kasinath V, Dai L, Eskandari SK, Bahmani B, Yonar M, Azzi JR, Haik Y, Sage PT, Murphy GF, Annabi N, Schatton T, Guleria I, Abdi R. Targeting antigen-presenting cells by anti-PD-1 nanoparticles augments antitumor immunity. JCI Insight. 2018;3:17.","journal-title":"JCI Insight"},{"key":"1966_CR89","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.canlet.2020.08.009","volume":"493","author":"H Tao","year":"2020","unstructured":"Tao H, Cheng L, Liu L, Wang H, Jiang Z, Qiang X, Xing L, Xu Y, Cai X, Yao J, Wang M, Qiu Z. A PD-1 peptide antagonist exhibits potent anti-tumor and immune regulatory activity. Cancer Lett. 2020;493:91\u2013101.","journal-title":"Cancer Lett"},{"key":"1966_CR90","first-page":"394","volume":"14","author":"D Killock","year":"2017","unstructured":"Killock D. Macrophages hijack anti-PD-1 therapy. Nat Rev Clin Oncol. 2017;14:394\u2013394.","journal-title":"Nat Rev Clin Oncol"},{"key":"1966_CR91","doi-asserted-by":"publisher","first-page":"814","DOI":"10.1038\/s41417-021-00367-9","volume":"29","author":"M Barati","year":"2022","unstructured":"Barati M, Mirzavi F, Nikpoor AR, Sankian M, Namdar Ahmadabad H, Soleimani A, Mashreghi M, Tavakol Afshar J, Mohammadi M, Jaafari MR. Enhanced antitumor immune response in melanoma tumor model by anti-PD-1 small interference RNA encapsulated in nanoliposomes. Cancer Gene Ther. 2022;29:814\u201324.","journal-title":"Cancer Gene Ther"},{"key":"1966_CR92","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3390\/nano9020159","volume":"9","author":"Y Wu","year":"2019","unstructured":"Wu Y, Gu W, Li L, Chen C, Xu ZP. Enhancing PD-1 gene silence in T lymphocytes by comparing the delivery performance of two inorganic nanoparticle platforms. Nanomaterials. 2019;9:159.","journal-title":"Nanomaterials"},{"key":"1966_CR93","doi-asserted-by":"publisher","first-page":"1480","DOI":"10.1016\/S1470-2045(18)30700-9","volume":"19","author":"FS Hodi","year":"2018","unstructured":"Hodi FS, Chiarion-Sileni V, Gonzalez R, Grob J-J, Rutkowski P, Cowey CL, Lao CD, Schadendorf D, Wagstaff J, Dummer R, Ferrucci PF, Smylie M, Hill A, Hogg D, Marquez-Rodas I, Jiang J, Rizzo J, Larkin J, Wolchok JD. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. Lancet Oncol. 2018;19:1480\u201392.","journal-title":"Lancet Oncol"},{"key":"1966_CR94","doi-asserted-by":"publisher","first-page":"4757","DOI":"10.1039\/D0BM00908C","volume":"8","author":"J Zhang","year":"2020","unstructured":"Zhang J, Liu D, Liu J, Han Y, Xu H, Leng X, Kong D, Liu L. Hybrid spherical nucleotide nanoparticles can enhance the synergistic anti-tumor effect of CTLA-4 and PD-1 blockades. Biomater Sci. 2020;8:4757\u201366.","journal-title":"Biomater Sci"},{"key":"1966_CR95","doi-asserted-by":"publisher","first-page":"4940","DOI":"10.1021\/acs.molpharmaceut.9b00826","volume":"16","author":"SY Kwak","year":"2019","unstructured":"Kwak SY, Lee S, Han HD, Chang S, Kim KP, Ahn HJ. PLGA nanoparticles codelivering siRNAs against programmed cell death protein-1 and its ligand gene for suppression of colon tumor growth. Mol Pharm. 2019;16:4940\u201353.","journal-title":"Mol Pharm"},{"key":"1966_CR96","doi-asserted-by":"publisher","first-page":"955","DOI":"10.2217\/nnm-2018-0237","volume":"14","author":"YH Wu","year":"2019","unstructured":"Wu YH, Gu WY, Li J, Chen C, Xu ZP. Silencing PD-1 and PD-L1 with nanoparticle-delivered small interfering RNA increases cytotoxicity of tumor-infiltrating lymphocytes. Nanomedicine. 2019;14:955\u201368.","journal-title":"Nanomedicine"},{"key":"1966_CR97","doi-asserted-by":"publisher","first-page":"1706098","DOI":"10.1002\/adma.201706098","volume":"30","author":"Y Mi","year":"2018","unstructured":"Mi Y, Smith CC, Yang F, Qi Y, Roche KC, Serody JS, Vincent BG, Wang AZ. A dual immunotherapy nanoparticle improves T-cell activation and cancer immunotherapy. Adv Mater. 2018;30:1706098.","journal-title":"Adv Mater"},{"key":"1966_CR98","doi-asserted-by":"publisher","first-page":"1424","DOI":"10.1021\/acs.nanolett.2c04767","volume":"23","author":"Y Fu","year":"2023","unstructured":"Fu Y, Huang Y, Li P, Wang L, Tang Z, Liu X, Bian X, Wu S, Wang X, Zhu B, Yu Y, Jiang J, Li C. Physical- and chemical-dually ROS-responsive nano-in-gel platforms with sequential release of OX40 agonist and PD-1 Inhibitor for augmented combination immunotherapy. Nano Lett. 2023;23:1424\u201334.","journal-title":"Nano Lett"},{"key":"1966_CR99","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1158\/2326-6066.CIR-14-0211","volume":"3","author":"PA Beavis","year":"2015","unstructured":"Beavis PA, Milenkovski N, Henderson MA, John LB, Allard B, Loi S, Kershaw MH, Stagg J, Darcy PK. Adenosine receptor 2A blockade increases the efficacy of anti\u2013PD-1 through enhanced antitumor T-cell responses. Cancer Immunol Res. 2015;3:506.","journal-title":"Cancer Immunol Res"},{"key":"1966_CR100","doi-asserted-by":"publisher","first-page":"120166","DOI":"10.1016\/j.lfs.2021.120166","volume":"288","author":"F Karoon Kiani","year":"2022","unstructured":"Karoon Kiani F, Izadi S, Ansari Dezfouli E, Ebrahimi F, Mohammadi M, Chalajour H, Mortazavi Bulus M, Nasr Esfahani M, Karpisheh V, Mahmoud Salehi Khesht A, Abbaszadeh-Goudarzi K, Soleimani A, Gholizadeh Navashenaq J, Ahmadi M, Hassannia H, Hojjat-Farsangi M, Shahmohammadi Farid S, Hashemi V, Jadidi-Niaragh F. Simultaneous silencing of the A2aR and PD-1 immune checkpoints by siRNA-loaded nanoparticles enhances the immunotherapeutic potential of dendritic cell vaccine in tumor experimental models. Life Sci. 2022;288:120166.","journal-title":"Life Sci"},{"key":"1966_CR101","doi-asserted-by":"publisher","first-page":"eaay7785","DOI":"10.1126\/sciadv.aay7785","volume":"6","author":"Z Xiao","year":"2020","unstructured":"Xiao Z, Su Z, Han S, Huang J, Lin L, Shuai X. Dual pH-sensitive nanodrug blocks PD-1 immune checkpoint and uses T cells to deliver NF-\u03baB inhibitor for antitumor immunotherapy. Sci Adv. 2020;6:eaay7785.","journal-title":"Sci Adv"},{"key":"1966_CR102","doi-asserted-by":"publisher","first-page":"1806957","DOI":"10.1002\/adma.201806957","volume":"31","author":"H Ruan","year":"2019","unstructured":"Ruan H, Hu Q, Wen D, Chen Q, Chen G, Lu Y, Wang J, Cheng H, Lu W, Gu Z. A Dual-bioresponsive drug-delivery depot for combination of epigenetic modulation and immune checkpoint blockade. Adv Mater. 2019;31:1806957.","journal-title":"Adv Mater"},{"key":"1966_CR103","doi-asserted-by":"publisher","first-page":"8956","DOI":"10.1021\/acsnano.6b04989","volume":"10","author":"Y Ye","year":"2016","unstructured":"Ye Y, Wang J, Hu Q, Hochu GM, Xin H, Wang C, Gu Z. Synergistic transcutaneous immunotherapy enhances antitumor immune responses through delivery of checkpoint inhibitors. ACS Nano. 2016;10:8956\u201363.","journal-title":"ACS Nano"},{"key":"1966_CR104","doi-asserted-by":"publisher","first-page":"1747","DOI":"10.1038\/s41467-017-01830-8","volume":"8","author":"D Schmid","year":"2017","unstructured":"Schmid D, Park CG, Hartl CA, Subedi N, Cartwright AN, Puerto RB, Zheng Y, Maiarana J, Freeman GJ, Wucherpfennig KW, Irvine DJ, Goldberg MS. T cell-targeting nanoparticles focus delivery of immunotherapy to improve antitumor immunity. Nat Commun. 2017;8:1747.","journal-title":"Nat Commun"},{"key":"1966_CR105","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1002\/anie.201804882","volume":"58","author":"X Duan","year":"2019","unstructured":"Duan X, Chan C, Lin W. Nanoparticle-mediated immunogenic cell death enables and potentiates cancer immunotherapy. Angew Chem Int Ed. 2019;58:670\u201380.","journal-title":"Angew Chem Int Ed"},{"key":"1966_CR106","doi-asserted-by":"publisher","first-page":"18885","DOI":"10.1039\/D0NR04213G","volume":"12","author":"XM Lan","year":"2020","unstructured":"Lan XM, Zhu WY, Huang XS, Yu YJ, Xiao HH, Jin LJ, Pu JYJ, Xie X, She JC, Lui VWY, Chen HJ, Su YX. Microneedles loaded with anti-PD-1-cisplatin nanoparticles for synergistic cancer immuno-chemotherapy. Nanoscale. 2020;12:18885\u201398.","journal-title":"Nanoscale"},{"key":"1966_CR107","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.nantod.2018.02.010","volume":"19","author":"S Gai","year":"2018","unstructured":"Gai S, Yang G, Yang P, He F, Lin J, Jin D, Xing B. Recent advances in functional nanomaterials for light\u2013triggered cancer therapy. Nano Today. 2018;19:146\u201387.","journal-title":"Nano Today"},{"key":"1966_CR108","doi-asserted-by":"publisher","first-page":"779","DOI":"10.3390\/ma12050779","volume":"12","author":"ACV Doughty","year":"2019","unstructured":"Doughty ACV, Hoover AR, Layton E, Murray CK, Howard EW, Chen WR. Nanomaterial applications in photothermal therapy for cancer. Materials. 2019;12:779.","journal-title":"Materials"},{"key":"1966_CR109","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.jconrel.2019.05.036","volume":"306","author":"N Zhang","year":"2019","unstructured":"Zhang N, Song J, Liu Y, Liu MZ, Zhang L, Sheng DL, Deng LM, Yi HJ, Wu M, Zheng YY, Wang ZG, Yang Z. Photothermal therapy mediated by phase-transformation nanoparticles facilitates delivery of anti-PD1 antibody and synergizes with antitumor immunotherapy for melanoma. J Control Release. 2019;306:15\u201328.","journal-title":"J Control Release"},{"key":"1966_CR110","doi-asserted-by":"publisher","first-page":"7647","DOI":"10.1021\/acsnano.8b00204","volume":"12","author":"LH Luo","year":"2018","unstructured":"Luo LH, Zhu CQ, Yin H, Jiang MS, Zhang JL, Qin B, Luo ZY, Yuan XL, Yang J, Li W, Du YZ, You J. Laser Immunotherapy in combination with perdurable PD-1 blocking for the treatment of metastatic tumors. ACS Nano. 2018;12:7647\u201362.","journal-title":"ACS Nano"},{"key":"1966_CR111","doi-asserted-by":"publisher","first-page":"2100437","DOI":"10.1002\/adfm.202100437","volume":"31","author":"T Gao","year":"2021","unstructured":"Gao T, Zhang Z, Liang S, Fu S, Mu W, Guan L, Liu Y, Chu Q, Fang Y, Liu Y, Zhang N. Reshaping antitumor immunity with chemo-photothermal integrated nanoplatform to augment checkpoint blockade-based vancer therapy. Adv Funct Mater. 2021;31:2100437.","journal-title":"Adv Funct Mater"},{"key":"1966_CR112","doi-asserted-by":"publisher","first-page":"5662","DOI":"10.1021\/acsnano.9b00892","volume":"13","author":"F Zhang","year":"2019","unstructured":"Zhang F, Li F, Lu G-H, Nie W, Zhang L, Lv Y, Bao W, Gao X, Wei W, Pu K, Xie H-Y. Engineering magnetosomes for ferroptosis\/immunomodulation synergism in cancer. ACS Nano. 2019;13:5662\u201373.","journal-title":"ACS Nano"},{"key":"1966_CR113","doi-asserted-by":"publisher","first-page":"3028","DOI":"10.1016\/j.apsb.2022.02.025","volume":"12","author":"X Shan","year":"2022","unstructured":"Shan X, Gong X, Li J, Wen J, Li Y, Zhang Z. Current approaches of nanomedicines in the market and various stage of clinical translation. Acta Pharm Sin B. 2022;12:3028\u201348.","journal-title":"Acta Pharm Sin B"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-023-01966-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-023-01966-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-023-01966-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,7,4]],"date-time":"2023-07-04T17:02:08Z","timestamp":1688490128000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnanobiotechnology.biomedcentral.com\/articles\/10.1186\/s12951-023-01966-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,4]]},"references-count":113,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1966"],"URL":"https:\/\/doi.org\/10.1186\/s12951-023-01966-4","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,4]]},"assertion":[{"value":"2 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"All authors consent to publish.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"207"}}